Literature DB >> 25806254

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi1, Tetsuya Mitsudomi2.   

Abstract

Pulmonary nodules with ground-glass opacity (GGO) are frequently observed and will be increasingly detected. GGO can be observed in both benign and malignant conditions, including lung cancer and its preinvasive lesions. Atypical adenomatous hyperplasia and adenocarcinoma in situ are typically manifested as pure GGOs, whereas more advanced adenocarcinomas may include a larger solid component within the GGO region. The natural history of GGOs has been gradually clarified. Approximately 20% of pure GGOs and 40% of part-solid GGOs gradually grow or increase their solid component, whereas others remain unchanged for years. Therefore, it remains unclear whether all pulmonary lesions with GGO should be surgically resected or whether lesions without changes may not require resection. To distinguish GGOs with growth from those without growth, a 3-year follow-up observation period is a reasonable benchmark based on the data that the volume-doubling time (VDT) of pure GGOs ranges from approximately 600 to 900 days and that of part-solid GGOs ranges from 300 to 450 days. Future studies on the genetic differences between GGOs with growth and those without growth will help establish an appropriate management algorithm.

Entities:  

Keywords:  Follow-up; ground-glass opacity (GGO); limited surgery; lung cancer; small lung lesion; volume doubling time (VDT)

Year:  2013        PMID: 25806254      PMCID: PMC4367726          DOI: 10.3978/j.issn.2218-6751.2013.09.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  49 in total

1.  Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years.

Authors:  Ken Kodama; Masahiko Higashiyama; Hideoki Yokouchi; Koji Takami; Keiko Kuriyama; Yoko Kusunoki; Tomio Nakayama; Fumio Imamura
Journal:  Ann Thorac Surg       Date:  2002-02       Impact factor: 4.330

2.  Volume-doubling time of pulmonary nodules with ground glass opacity at multidetector CT: Assessment with computer-aided three-dimensional volumetry.

Authors:  Seitaro Oda; Kazuo Awai; Kohei Murao; Akio Ozawa; Daisuke Utsunomiya; Yumi Yanaga; Koichi Kawanaka; Yasuyuki Yamashita
Journal:  Acad Radiol       Date:  2011-01       Impact factor: 3.173

3.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

4.  Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience.

Authors:  Junji Yoshida; Kanji Nagai; Tomoyuki Yokose; Mitsuyo Nishimura; Ryutaro Kakinuma; Hironobu Ohmatsu; Yutaka Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

5.  Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact.

Authors:  Kenji Suzuki; Masahiko Kusumoto; Shun-ichi Watanabe; Ryosuke Tsuchiya; Hisao Asamura
Journal:  Ann Thorac Surg       Date:  2006-02       Impact factor: 4.330

6.  CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern.

Authors:  Shodayu Takashima; Yuichiro Maruyama; Minoru Hasegawa; Takeshi Yamanda; Takayuki Honda; Masumi Kadoya; Shusuke Sone
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

7.  Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: A predictor of lymph node metastasis.

Authors:  Haruhisa Matsuguma; Kohei Yokoi; Masaki Anraku; Tetsuro Kondo; Yukari Kamiyama; Kiyoshi Mori; Keigo Tominaga; Yukio Tsuura; Satoshi Honjo
Journal:  J Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 5.209

8.  Treatment strategy for patients with small peripheral lung lesion(s): intermediate-term results of prospective study.

Authors:  Ken Kodama; Masahiko Higashiyama; Koji Takami; Kazuyuki Oda; Jiro Okami; Jun Maeda; Mitsuhiro Koyama; Tomio Nakayama
Journal:  Eur J Cardiothorac Surg       Date:  2008-08-28       Impact factor: 4.191

9.  The long-term course of ground-glass opacities detected on thin-section computed tomography.

Authors:  Sei Won Lee; Cho-Sun Leem; Tae Jung Kim; Kyung Won Lee; Jin-Haeng Chung; Sanghoon Jheon; Jae-Ho Lee; Choon-Taek Lee
Journal:  Respir Med       Date:  2013-03-17       Impact factor: 3.415

10.  A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions.

Authors:  Hisao Asamura; Kenji Suzuki; Shun-ichi Watanabe; Yoshihiro Matsuno; Arafumi Maeshima; Ryosuke Tsuchiya
Journal:  Ann Thorac Surg       Date:  2003-10       Impact factor: 4.330

View more
  36 in total

1.  Bilateral uniportal video-assisted thoracic surgery segmentectomy S3: an unusual case.

Authors:  Alonso José Oviedo Argueta; Sonia Raquelline Roque Cañas; Yuming Zhu; Diego Gonzalez-Rivas
Journal:  J Vis Surg       Date:  2017-11-11

2.  Computed tomography and pathology evaluation of lung ground-glass opacity.

Authors:  Hualong Yu; Shihe Liu; Chuanyu Zhang; Shaoke Li; Jianan Ren; Jingli Zhang; Wenjian Xu
Journal:  Exp Ther Med       Date:  2018-10-22       Impact factor: 2.447

3.  Diagnosis of COVID-19, vitality of emerging technologies and preventive measures.

Authors:  Muhammad Asif; Yun Xu; Fei Xiao; Yimin Sun
Journal:  Chem Eng J       Date:  2021-05-07       Impact factor: 13.273

4.  Standardized uptake value and radiological density attenuation as predictive and prognostic factors in patients with solitary pulmonary nodules: our experience on 1,592 patients.

Authors:  Duilio Divisi; Mirko Barone; Luca Bertolaccini; Gaetano Rocco; Piergiorgio Solli; Roberto Crisci
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

5.  Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma.

Authors:  Claudio R Scafoglio; Brendon Villegas; Gihad Abdelhady; Sean T Bailey; Jie Liu; Aditya S Shirali; W Dean Wallace; Clara E Magyar; Tristan R Grogan; David Elashoff; Tonya Walser; Jane Yanagawa; Denise R Aberle; Jorge R Barrio; Steven M Dubinett; David B Shackelford
Journal:  Sci Transl Med       Date:  2018-11-14       Impact factor: 17.956

6.  Optimal management of pulmonary ground-glass opacity nodules.

Authors:  Yeon Wook Kim; Choon-Taek Lee
Journal:  Transl Lung Cancer Res       Date:  2019-12

7.  Ground glass nodules with 5 years' stability can grow after 10-year follow-up: do genetic features determine the fate?

Authors:  Yoshihisa Kobayashi; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 8.  Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures.

Authors:  Gajanan Sampatrao Ghodake; Surendra Krushna Shinde; Avinash Ashok Kadam; Rijuta Ganesh Saratale; Ganesh Dattatraya Saratale; Asad Syed; Abdallah M Elgorban; Najat Marraiki; Dae-Young Kim
Journal:  Biosens Bioelectron       Date:  2021-01-04       Impact factor: 10.618

9.  Pleural dissemination of a mixed ground-glass opacity nodule treated as a nontuberculous mycobacterial infection for 6 years without growing remarkably.

Authors:  Shuichi Shinohara; Kouji Kuroda; Hidehiko Shimokawa; Taiji Kuwata; Masaru Takenaka; Yasuhiro Chikaishi; Souichi Oka; Ayako Hirai; Naoko Imanishi; Hidetaka Uramoto; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

Review 10.  Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights.

Authors:  Yoshihisa Kobayashi; Chiara Ambrogio; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.